Japan approves Genmab’s EPKINLY for R/R follicular lymphoma treatment
Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY or epcoritamab, for the treatment of ...
Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference
Media ReleaseCOPENHAGEN, Denmark; February 19, 2025Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano and Chief Development Officer Judith Klimovsky will ...
Gambling.com gains after strong Q4 earnings, confident outlook
Shares of Gambling.com ( GMAB) were up 4.2% in premarket action to $16.88 vs. the 52-week range of $7.52 to $17.14. The stock ...
Genmab (GMAB) Gets a Hold from Morgan Stanley
Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Genmab (GMAB – Research Report) today and set a price target of $31.00. The ...
Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon
Genmab's Q4 2024 results impress with $897.4M revenue and 29% growth. GMAB's balance sheet is strong with nearly $3 billion ...
Leerink Partnrs Estimates Genmab A/S Q3 Earnings
Research analysts at Leerink Partnrs issued their Q3 2025 EPS estimates for shares of Genmab A/S in a report issued on Thursday, February 13th. Leerink Partnrs analyst J. Chang forecasts that the ...
Q3 Earnings Forecast for Genmab A/S Issued By William Blair
Equities researchers at William Blair issued their Q3 2025 earnings per share estimates for Genmab A/S in a research note issued on Thursday, February 13th. William Blair analyst M. Phipps forecasts ...